SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MultiCell Technologies, Inc.
MCET 0.000010000.0%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RWS who wrote (94)10/24/2005 9:33:05 AM
From: Tradenride  Read Replies (1) of 237
 
RWS, what the PR does not tell the public is that a 90% in reduction of the H1N1 Strain is the same as 10%. The strain revives itself. The eggs continuously manufacture themselves. MCET is no closer to curing the flu than it is the common cold.

Here are the facts:

"existing
immunomodulatory drugs are like using a
sledgehammer to hit a tack, and the side
effects of drugs like interferon alpha and
IL-2 are notorious." and

"Despite a promising immune response,
there is no quick fix to the limited eggbased
manufacturing capacity" and

"Probably, there will be no
total exclusivity possible.’"

nexbio.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News